ABSTRACT
It is believed, but not well established, that renal dysfunction increases the risk of adverse bleeding events associated with dual antiplatelet therapy (DAPT), especially in patients with acute coronary syndrome (ACS). The aim of this study is to estimate the impact of renal function on adverse bleeding events associated with DAPT in patients with ACS. A total of 1,264 ACS patients who received DAPT, clopidogrel (n = 530) or prasugrel (n = 734) in addition to aspirin, were assessed in a multicenter observational study. The relationship between renal function and bleeding event, defined as BARC 3 or 5, was determined using a marginal effect from the logit model and Royston-Parmar model. During an average 313.1 days of the observation period, defined as the duration of DAPT after admission until the implementation of a change in the regimen, bleeding events were observed in 7.4% of patients (n = 94). The estimated curves demonstrated that the probability of bleeding was positive correlated with renal dysfunction (6.0 to 8.6), regardless of the DAPT regimen used. This probability was consistently higher in clopidogrel (7.4 to 10.5) than in prasugrel (4.8 to 0.7). This trend was also shown in maintenance hemodialysis patients (6.7 vs. 10.3). Estimated cumulative incidences among individual stages of renal function were drawn. In conclusion, bleeding events increased with worsening renal function, and prasugrel is safer than clopidogrel as a component of DAPT throughout all levels of renal function, including hemodialysis patients after ACS.
Subject(s)
Acute Coronary Syndrome , Kidney Diseases , Percutaneous Coronary Intervention , Humans , Platelet Aggregation Inhibitors/adverse effects , Clopidogrel/adverse effects , Prasugrel Hydrochloride/adverse effects , Ticlopidine/adverse effects , Acute Coronary Syndrome/therapy , Drug Therapy, Combination , Hemorrhage/chemically induced , Hemorrhage/epidemiology , Kidney Diseases/chemically induced , Kidney , Percutaneous Coronary Intervention/adverse effects , Treatment OutcomeSubject(s)
Aortic Valve Stenosis , Heart Valve Prosthesis , ST Elevation Myocardial Infarction , Transcatheter Aortic Valve Replacement , Humans , Transcatheter Aortic Valve Replacement/adverse effects , ST Elevation Myocardial Infarction/diagnostic imaging , ST Elevation Myocardial Infarction/etiology , ST Elevation Myocardial Infarction/therapy , Aortic Valve/diagnostic imaging , Aortic Valve/surgery , Aortic Valve Stenosis/diagnostic imaging , Aortic Valve Stenosis/surgery , Treatment OutcomeABSTRACT
BACKGROUND: This study estimates the temporal risk variations of ischemic and bleeding events during dual antiplatelet therapy (DAPT) among patients stratified according to the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria, suggesting the optimal period for DAPT after acute coronary syndrome (ACS). METHODS: A total of 1264 ACS patients receiving either clopidogrel or prasugrel with aspirin were classified by ARC-HBR; HBR (n = 574) and non-HBR groups (n = 690). This study was designed as a multicenter observation to evaluate the primary endpoints of ischemic, including cardiovascular death, myocardial infarction, or ischemic stroke, and bleeding events, defined as Bleeding Academic Research Consortium type 3/5. The temporal risk variations were estimated using the Cox hazard and Royston-Parmar models. RESULTS: Ischemic and bleeding events were observed in 9.4% and 7.4%, respectively, during an average observation period of 313 days. The HBR group had a higher incidence of both events than the non-HBR group (15.3% vs. 4.5%, P < 0.01 for ischemic; 11.9% vs. 3.8%, P < 0.01 for bleeding). The estimated risk curves for both events revealed peaks and steep declines in the first few days, followed by constant declines. The peak of risk was higher for bleeding than for ischemic events, but this relationship reversed early, with ischemic events displaying a higher risk in both the HBR and non-HBR groups until at least 60 days. CONCLUSIONS: A 60-day period of DAPT is appropriate to balance the risks of adverse events after ACS, regardless of ARC-HBR criteria.
Subject(s)
Acute Coronary Syndrome , Percutaneous Coronary Intervention , Humans , Platelet Aggregation Inhibitors/adverse effects , Acute Coronary Syndrome/diagnosis , Acute Coronary Syndrome/drug therapy , Acute Coronary Syndrome/epidemiology , Stents , Hemorrhage/chemically induced , Hemorrhage/diagnosis , Hemorrhage/epidemiology , Dual Anti-Platelet Therapy/adverse effects , Percutaneous Coronary Intervention/adverse effects , Treatment OutcomeABSTRACT
Traditionally, two bigger-sized guiding catheters (GCs) via the femoral artery have been used in percutaneous coronary intervention (PCI) for chronic total occlusion (CTO). However, those GCs are associated with an increased incidence of bleeding. Therefore, the use of smaller GCs (e.g., 5-Fr) may lessen the invasiveness of this procedure. However, the use of 5-Fr GCs in PCI is complicated by device limitations. A novel technique was developed to overcome the challenges with regard to kissing balloon inflation. This approach involves simultaneous balloon inflation through a dual 5-Fr GC technique for CTO-PCI. In our hospital, this technique was successfully performed in 9 cases of CTO with 10 bifurcated lesions (including four left main-related bifurcations). During the study period, there was no requirement for an additional invasive procedure or occurrence of complications related to the PCI procedure. This technique may be a good option for performing KBI during CTO-PCI through the use of two 5-Fr GCs.
Subject(s)
Angioplasty, Balloon, Coronary , Coronary Occlusion , Percutaneous Coronary Intervention , Humans , Percutaneous Coronary Intervention/adverse effects , Percutaneous Coronary Intervention/methods , Treatment Outcome , Coronary Occlusion/diagnostic imaging , Coronary Occlusion/therapy , Catheters , Coronary Angiography/methods , Chronic DiseaseABSTRACT
BACKGROUND: The usefulness of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in the selection of P2Y12 receptor inhibitors for acute coronary syndrome is unknown. This study investigated whether the selection of antiplatelet agents according to the ARC-HBR criteria could improve clinical outcomes. METHODS: This multicenter retrospective study included 1261 patients with acute coronary syndrome who received dual antiplatelet therapy, namely clopidogrel (75 mg, n = 529) or prasugrel (3.75 mg, n = 732) in addition to aspirin. The primary endpoint was net adverse clinical events (NACE) after hospital admission, including ischemic (death, myocardial infarction, ischemic stroke) and bleeding events (Bleeding Academic Research Consortium 3 or 5). Secondary outcomes were ischemic and bleeding events. For each patient, the observation period was defined as the duration of dual antiplatelet therapy after admission. RESULTS: During the observation period (average: 313 days), the rate of NACE was lower in the prasugrel group than the clopidogrel group (20.6% vs. 12.6%, respectively, P < 0.01). In patients who satisfied or did not satisfy the ARC-HBR criteria, prasugrel was associated with a 3.7% and 2.1% lower incidence of NACE, respectively, versus clopidogrel. Ischemic and bleeding events were less frequent in the prasugrel group than the clopidogrel group (11.5% vs. 7.9%, respectively, P = 0.03; 10.6% vs. 5.2%, respectively, P < 0.01). The estimated incidence models for NACE suggested that the difference between clopidogrel and prasugrel was greater in patients who satisfied the ARC-HBR criteria than in those who did not. CONCLUSIONS: Prasugrel is preferable to clopidogrel regardless of the ARC-HBR.
Subject(s)
Acute Coronary Syndrome , Percutaneous Coronary Intervention , Humans , Platelet Aggregation Inhibitors/adverse effects , Clopidogrel/adverse effects , Prasugrel Hydrochloride/adverse effects , Acute Coronary Syndrome/diagnosis , Acute Coronary Syndrome/drug therapy , Acute Coronary Syndrome/epidemiology , Purinergic P2Y Receptor Antagonists/adverse effects , Retrospective Studies , Treatment Outcome , Hemorrhage/chemically induced , Hemorrhage/diagnosis , Hemorrhage/epidemiology , Percutaneous Coronary Intervention/adverse effectsABSTRACT
Although coronavirus disease 2019 (COVID-19) vaccination is known to carry a slight risk of myocarditis and pericarditis, it remains unclear whether it has any impact on coronary artery disease. Here we present a case without particular thrombotic diathesis with a diagnosis of ST segment elevation acute myocardial infarction (STEMI) 19 h after a third dose of a COVID-19 mRNA vaccine. A primary percutaneous coronary intervention procedure for occluded right coronary artery with thrombus aspiration alone was successful in this patient. However, the relationship between STEMI and COVID-19 mRNA vaccination is uncertain, and additional studies to validate thrombogenetic effects of COVID-19 mRNA vaccines are needed. This case was helpful in distinguishing STEMI from myocarditis and pericarditis, which are recognized rare cardiac side effects of COVID-19 vaccination. It is important not to hesitate to perform coronary angiography procedures to rule out the possibility of STEMI occurrence, as in this case.
Subject(s)
COVID-19 Vaccines , COVID-19 , Myocarditis , Percutaneous Coronary Intervention , Pericarditis , ST Elevation Myocardial Infarction , Thrombosis , Humans , Coronary Angiography , COVID-19/complications , COVID-19 Vaccines/adverse effects , mRNA Vaccines , Percutaneous Coronary Intervention/methods , ST Elevation Myocardial Infarction/diagnostic imaging , ST Elevation Myocardial Infarction/therapy , Treatment OutcomeABSTRACT
Objective This study examined the ability of a combination of biomarkers, including N-terminal pro-B-type natriuretic peptide (N-BNP) and high-sensitivity C-reactive protein (hs-CRP), to better predict mortality than the Global Registry of Acute Coronary Events (GRACE) score in acute myocardial infarction (AMI) patients who received primary percutaneous coronary intervention (PPCI). Methods The in-hospital mortality in 754 all-comer patients with AMI who underwent successful PPCI over 8 years was examined. A receiver operating characteristic (ROC) analysis was performed to determine the in-hospital mortality in a single center. A logistic regression analysis was used to compare the predictive accuracy of the GRACE score and biomarkers. The incremental predictive value of those biomarkers beyond the GRACE score was also examined. Results The mean age was 66±13 years old, and 609 patients with ST-elevated AMI (80.8%) were included. The in-hospital mortality was 6.8%. The GRACE score (in-hospital survivor/non-survivor: 106±33/161±32; p<0.05,) and N-BNP (in-hospital survivor/non-survivor: 2,458±7,058/8,880±1,1331 pg/mL; p<0.05) were significantly lower in survivors than in non-survivors. The area under the ROC curve (AUC) of in-hospital mortality of the GRACE score was significantly higher than that of the dual-biomarker combination (0.868/0.720; p<0.05). The AUC of the combination of the GRACE score and dual-biomarkers was not significantly higher than that of the GRACE score alone (0.870/0.868; p=0.747). Conclusion The measurement of representative cardiovascular biomarkers did not provide any additional benefit for mortality prediction beyond the GRACE score in AMI patients who received PPCI.
Subject(s)
Acute Coronary Syndrome , Myocardial Infarction , Percutaneous Coronary Intervention , Humans , Middle Aged , Aged , Myocardial Infarction/diagnosis , Myocardial Infarction/surgery , Biomarkers , ROC Curve , Registries , Risk Assessment , Prognosis , Risk FactorsSubject(s)
Coronary Artery Disease , Coronary Vessel Anomalies , Fistula , Heart Defects, Congenital , Humans , Heart VentriclesABSTRACT
A 78-year-old female diagnosed with effort angina underwent coronary angiography. The findings revealed subtotal occlusion in the tortuous circumflex. The lesion was initially treated with a drug-coated balloon alone; however, restenosis occurred after 2â¯months. Thus, percutaneous coronary intervention was performed again using a drug-eluting stent (DES) through a 5-Fr guiding catheter to minimize invasiveness. However, it was not possible to pass the lesion with the DES; thus, a novel guide extension catheter with a rapid exchange system was passed under balloon anchoring against the tortuous artery. The use of this guide extension catheter resulted in the successful delivery and implantation of the DES. This approach, using a novel guide extension catheter with a rapid exchange system through a 5-Fr guiding catheter, may facilitate the implantation of devices. Learning objective: Smaller guiding catheter (GC) using a 5-Fr contributes less invasive percutaneous coronary intervention (PCI) procedure for patients. However, sometimes GC stability and device pushability become insufficient in using 5-Fr GC. Hence, we report a case of PCI procedure through a 5-Fr GC with novel guide extension catheter, and it may be an alternative option when GC stability and device pushability are insufficient. It is meaningful to share this method of PCI procedure for all physicians.
ABSTRACT
Conventional radial access (cRA) for percutaneous coronary intervention (PCI) has become the current standard due to low bleeding complications, although recently, distal radial access (dRA) has attracted attention as an alternative. Here, the usefulness of dRA is shown in a case in whom neither side could be used for cRA. The patient was a woman in her 70 s diagnosed with unstable angina pectoris at another hospital. Although ad hoc PCI was attempted via her right forearm radial artery, her hemodynamics deteriorated and the procedure was abandoned. After an intra-aortic balloon pumping device was inserted via the left femoral approach and hemostasis was established with a dedicated device, the patient was transferred to our hospital. Her right radial artery was being used for hemostasis and her left radial artery was poorly palpable. Because her right distal radial artery was palpable, access via that location was attempted after confirming sufficient blood vessel diameter and blood flow by ultrasound. A 6Fr sheath was inserted and PCI was safely accomplished. Hemostasis on dRA was completed without complications using a hemostasis device. Thus, dRA may be an option as an alternative access site in an emergency.
ABSTRACT
Recently, the efficacy was demonstrated of the Diamondback 360® Coronary Orbital Atherectomy System (OAS) (Cardiovascular Systems, Inc., St. Paul, MN, USA) for treating calcified coronary lesions in percutaneous coronary intervention (PCI). The safety and feasibility of OAS application through a 5-Fr guiding catheter (GC) which is less invasive and reduces access site complications were validated. This sequential, retrospective, observational study was conducted in a single center from September 2018 to May 2020. The primary endpoint was a successful PCI with the OAS. Secondary endpoints were major adverse complications related to PCI with the OAS, including coronary dissection, perforation, side branch loss, need for an unexpected cardiac assist device, access site complications, and major adverse cardiac and cerebrovascular events. 33 PCIs in 30 patients (mean age 72 ± 11 years; male, 83.3%) were surveyed. All PCIs were successfully completed with OAS application through a 5-Fr GC. Coronary perforation after the OAS procedure occurred in one case (3.0%). Severe coronary dissection occurred in three cases (9.1%), and procedural myocardial infarction in two cases (6.1%). Regarding PCIs performed with the 5-Fr GC, the OAS is a safe and feasible strategy for calcified plaque modification.
Subject(s)
Atherectomy, Coronary , Coronary Artery Disease , Percutaneous Coronary Intervention , Vascular Calcification , Aged , Aged, 80 and over , Atherectomy/methods , Atherectomy, Coronary/adverse effects , Catheters , Coronary Angiography , Coronary Artery Disease/therapy , Humans , Male , Middle Aged , Percutaneous Coronary Intervention/methods , Retrospective Studies , Severity of Illness Index , Time Factors , Treatment Outcome , Vascular Calcification/surgeryABSTRACT
OBJECTIVES: The transradial approach (TRA) is recommended in coronary catheterization due to the lower rate of bleeding complications compared with the transfemoral approach. However, a disadvantage of TRA is difficulty in puncturing under palpation of the radial pulse alone without arterial visibility. To overcome this limitation, a vessel visualization device using near-infrared rays, Art View (Forte Grow Medical Company), was used in the puncture of the radial artery (RA). METHODS: Patients who underwent coronary angiography via the right RA with Art View were retrospectively surveyed. According to the quality of RA visibility, the performance of the Art View was rated as follows: 5 = excellent; 4 = good; 3 = fair; 2 = not good; and 1 = poor. The primary endpoint was the procedural success of TRA using the Art View device. The secondary endpoints were procedural time (from injection of local anesthesia to successful crossing of the guidewire attached to the sheath), number of RA punctures, and change of puncture method or approach site. RESULTS: The Art View device was used in 38 patients (mean age, 71 ± 11 years). Puncturing of the visualized RA was successful in 30 patients (79.0%). Among successful cases, the mean procedural time was 142 ± 87 seconds. The success rates of each visualization evaluation were 100%, 100%, 84.6%, 33.3%, and 0% from grades 5 to 1, respectively (P<.01). The mean procedural times were 92 ± 18 seconds, 102 ± 58 seconds, 180 ± 75 seconds, 306 ± 80 seconds, and not available from grades 5 to 1, respectively (P<.01). CONCLUSION: The Art View RA visualization device is useful for RA puncture.
Subject(s)
Infrared Rays , Radial Artery , Aged , Aged, 80 and over , Coronary Angiography , Humans , Middle Aged , Radial Artery/diagnostic imaging , Radial Artery/surgery , Retrospective Studies , Treatment OutcomeABSTRACT
AIM: To predict platelet accumulation around stent struts in the presence or absence of tissue defects around them. METHODS: Computer simulations were performed using virtual platelets implementing the function of the three membrane proteins: glycoprotein (GP) Ibα, GPIIb/IIIa, and GPVI. These platelets were perfused around the stent struts implanted into the vessel wall in the presence or absence of tissue defects around them using within the simulation platform. The number of platelets that adhered around stent struts was calculated by solving the blood flow using Navier-Stokes equation along with the adhesion of membrane protein modeled within the platform. RESULTS: Platelet accumulation around stent struts occurred mostly at the downstream region of the stent strut array. The majority of platelets adhered at the downstream of the first bend regardless of the tissue defect status. Platelet adhesion around stent struts occurred more rapidly in the presence of tissue defects. CONCLUSION: Computer simulation using virtual platelets suggested a higher rate of platelet adhesion in the presence of tissue defects around stent struts.
Subject(s)
Platelet Adhesiveness/physiology , Platelet Membrane Glycoproteins/metabolism , Stents/adverse effects , Blood Circulation , Blood Platelets/physiology , Blood Vessels/injuries , Computer Simulation , HumansABSTRACT
There is no established hemostasis method or protocol for the transdistal radial approach. Therefore, this study aimed to determine whether "the PreludeSYNC DISTAL" radial compression device (PSD; Merit Medical Systems, Inc., South Jordan, UT) can effectively prevent distal radial artery (dRA) occlusion following catheterization procedures. This retrospective study analyzed patients who underwent hemostasis using the PSD from January 1, 2019, to March 31, 2019. The primary endpoint was occlusion or excessive stenosis of the radial artery (RA) 1 month after catheterization. Pulsatile blood flow and vessel diameters of the dRA and forearm RA (fRA) were measured using vascular ultrasound before and 1 month after catheterization to determine arterial damage. Secondary endpoints were achievement of hemostasis, bleeding, hematoma, aneurysm, neurological abnormality, and functional disturbance of the fingers or hand. Fifty patients (mean age, 70.9 ± 10.7 years; male, 72.0%) were enrolled in this study. Complete hemostasis was achieved in all cases. Total hemostasis time was 161 ± 45 min. No procedure-associated complications were noted. Pulsations of the dRA and fRA were maintained at 1 month. No functional disturbance or neurological abnormality was observed. Vessel diameters of the dRA and fRA were not significantly different before and 1 month after catheterization. No dissection, pseudoaneurysm, or occlusion/stenosis was observed on ultrasound. Distal radial access with a unique device and protocol effectively achieved hemostasis and prevented injury and occlusion of the dRA and fRA.
Subject(s)
Cardiac Catheterization/methods , Catheterization, Peripheral/methods , Coronary Artery Disease/surgery , Hemostatic Techniques/instrumentation , Ultrasonography/methods , Aged , Female , Humans , Male , Prospective Studies , Radial Artery , Retrospective StudiesABSTRACT
A 60 year-old man presenting with chest pain was diagnosed with acute ST-elevated myocardial infarction. An emergency coronary angiography showed distal left circumflex artery (LCX) occlusion. The ostium of the right coronary artery (RCA) was not detectable. Following primary percutaneous coronary intervention in the occluded LCX, we confirmed that RCA region was fed from both LAD and LCX. Coronary computed tomography showed similar findings. This single coronary artery anomaly is extremely rare and cannot be categorized according to the established classification system.
Subject(s)
Coronary Vessels/diagnostic imaging , Electrocardiography , Percutaneous Coronary Intervention/methods , ST Elevation Myocardial Infarction/diagnosis , Coronary Angiography , Coronary Vessels/surgery , Humans , Male , Middle Aged , ST Elevation Myocardial Infarction/surgery , Tomography, X-Ray ComputedABSTRACT
A 73 year-old male who underwent coronary artery bypass surgery (CABG) 8 years ago had PCI performed on him for a diffuse calcified stenotic lesion in the right coronary artery (RCA). Following 2.5 mm non-compliant balloon dilatation supported with a child catheter (Dio from Goodman), we implanted a stent to the distal RCA through this catheter. However, because the tip of Dio was trapped by the implanted stent, it was stretched and almost ruptured by pulling it. Next, we tried to implant a stent for mid RCA with buddy wire technique, but we could not deploy it because of calcification. When we tried to withdraw this stent system, the stent was accidentally dislodged from the balloon. We could withdraw the stent with twisting two wires. However, because one of these wires had crossed a small artery in the distal RCA at twisting, a tip of this wire was fractured when the stent was removed. We could remove this wire with gooseneck snare. Finally, we successfully implanted stents in the mid RCA with balloon anchor technique and to the proximal RCA.
Subject(s)
Coronary Artery Bypass/methods , Coronary Artery Disease/surgery , Coronary Vessels/surgery , Percutaneous Coronary Intervention/methods , Postoperative Complications/surgery , Renal Dialysis/adverse effects , Aged , Coronary Artery Bypass/adverse effects , Humans , Male , Stents , Treatment OutcomeABSTRACT
The familial variant of cardiac myxomas is an autosomally dominant disease. Here, we report a case of recurrent multiple cardiac myxomas wherein the patient, a 36-year-old woman who was referred for palpitations and nocturnal dyspnea, had a relevant familial history. Her mother had undergone extirpation of cardiac myxoma when she was about 50 years old. Echocardiography showed the presence of multiple cardiac myxomas. One of the cardiac myxomas nearly obstructed the left ventricular inflow; therefore, we extirpated the myxomas under cardiopulmonary bypass and cardioplegic arrest. The operation was uneventful and the postoperative clinical course was good. Pathological examination confirmed that the extirpated mass was a myxoma. Approximately 3 years after the first cardiac operation, we found a recurrent cardiac myxoma in the same patient. She then underwent a second operation and was discharged without any complications. Pathological examination also confirmed that the cardiac mass was a myxoma and that there was no malignancy.
ABSTRACT
A 52-year-old woman presenting with shortness of breath and having no related past medical history was diagnosed with takotsubo cardiomyopathy. However, she revealed respiratory failure atypical with takotsubo cardiomyopathy. We diagnosed myasthenia gravis with myasthenic crisis by acetylcholine receptor-binding antibody titer with mediastinal tumor. Physical or emotional stress is well known to trigger the onset of takotsubo cardiomyopathy. Similarly, myasthenia crisis is also triggered by stress. Here, we report a case of simultaneous occurrence of takotsubo cardiomyopathy and myasthenia crisis.
ABSTRACT
Although sirolimus-eluting stent (SES) is effective to reduce restenosis, the effect of SES for patients with chronic kidney disease (CKD) has been ambiguous. SES were exclusively implanted into 304 lesions in 195 patients. Forty-seven percent of the patients had diabetes. Patients were divided into three groups by estimated glomerular filtration rate, CKD stage 0-2: 156 patients, 239 lesions; CKD stage 3-4: 21 patients, 37 lesions; and CKD stage 5: 18 patients, 28 lesions. Clinical follow-up data were available in 97% at 616 ± 192 days. There was a statistically significant association between the stage of CKD and target lesion revascularization (TLR) (CKD 0-2: 2.7%, CKD 3-4: 5.3%, and CKD 5: 11.9%; P = 0.011), and late lumen loss at 8 months (CKD 0-2: 0.13 ± 0.25 mm, CKD 3-4: 0.27 ± 0.47 mm, and CKD 5: 0.37 ± 0.61 mm; P = 0.0032). The frequency of clinical adverse events was also higher according to stages of CKD. In conclusion, stages of CKD proportionally correlated with TLR, late lumen loss and major adverse cardiac events following SES implantation.
ABSTRACT
BACKGROUND: Several studies have indicated that the clinical outcomes of sirolimus-eluting stents (SES) are significantly associated with longitudinal positioning of the stent relative to the underlying plaque distribution. METHODS AND RESULTS: Optimal SES landing was determined using unique stepwise intravascular ultrasound (IVUS) criteria, mainly targeting the sites with plaque burden <50% (plaque area/external elastic membrane area x100). To verify the criteria, (1) achievability and (2) actual impact on clinical and angiographic outcomes were assessed. A total of 162 consecutive patients with 180 lesions were enrolled and treated according to the IVUS criteria. Plaque burden at the proximal and distal margins was 41.4+/-13.6% (n=144) and 34.9+/-15.6% (n=170), respectively (within 3 mm of stent ends). The target was achieved in 72.3% of the proximal and 84.1% of the distal margin for the criteria. A strikingly low angiographic margin re-stenosis rate (2.7% of proximal and 1.4% of distal margin) and low target lesion revascularization rate (2.2%) were achieved. Receiver operator characteristic curve indicated that plaque burden was the strongest predictor of margin re-stenosis and its threshold (51.6%) was almost identical to that of the criteria. CONCLUSIONS: The proposed stepwise IVUS criteria mainly targeting plaque burden <50% are feasible and useful in the real-world practice of SES implantation.